TOVX: Synthetic Biologics Net earnings per share (EPS TTM)

Theriva Biologics (TOVX) - corporate logo

Theriva Biologics, Inc. (TOVX) business relies on Phase 2/3 test results and the fight against infections in cancer patients, as illustrated by the 12-month EPS trend, where the indicator level stands at -0.25. A stable staff of leading oncologists and biotech experts minimizes talent attrition in R&D. However, the lack of commercial products and a small market capitalization create high stock volatility.

TOVX Theriva Biologics, Inc. Net earnings per share for the last 12 months (04/28/2023 - 11/18/2026)

Summary analytical data breakdowns for Theriva Corp (TOVX)

- share price and expert price forecast:
Fundamental valuation:TOVX - Theriva Corp
Flagship merchandise of Synthetic Biologics

This indicator reflects the actual profit share per common share over a rolling year. By analyzing the net income per share over a 12-month period, an investor sees the final financial result net of all expenses. The metric is sensitive to changes in the number of securities and the volume of net income. For Theriva Biologics, Inc. (TOVX), this is critical due to the massive costs of clinical trials. Should the patents succeed, the low cost of therapy will ensure a sharp spike in this metric.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)